Skip to content

Author

Tyler K. Ulland

2 papers indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Open access Sep 2026

The anti-leukemia drug ponatinib attenuates NLRP3 inflammasome activation in macrophages

The NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome is an established driver of inflammation in diseases such as diabetes, Alzheimer's disease, and gout. Previously, we screened 875 FDA-approved drugs for NLRP3 inhibitors and identified ponatinib as one of the five candidates that reduced NLRP3...

Abigail H. Evered, Daniel C. Shippy, Jaidynne N. Lash et al. · 0 citations
Open access Jul 2026

Equol inhibits NLRP3 inflammasome activation in macrophages 2257578

This work indicates equol’s anti-inflammatory effects are specific to the NLRP3 inflammasome; treatment with equol does not alter the secretion of several other inflammatory cytokines/chemokines or activation of the AIM2 or NLRC4 inflammasomes in BMDMs.

Abigail H. Evered, Daniel C. Shippy, T. Ulland · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.